Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Says Best is yet to Come in 2018
DehydraTECH™ is the company’s newly U.S.-patented disruptive drug delivery platform; LXRP CEO Chris Bunka says company is working on more applications for its technology in the treatment of Alzheimer’s disease, Parkinson’s disease, opioid addiction and more LXRP has a portfolio of patents issued in both the U.S. and Australia, plus 19 patent applications filed in the U.S. (and internationally using the Patent Cooperation Treaty), as well as national filings in 44 countries Company has diverse revenue streams, including out-licensing its technology to third parties with fees ranging from five to 10 percent of gross sales, as well as sales of…